Investee company update: RoseMonkey Ltd

Craven House Capital PLC

10 September 2024

 

Craven House Capital PLC

10 September 2024

Certain information contained within this Announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR") as applied in the United Kingdom. Upon publication of this Announcement, this information is now considered to be in the public domain.

Craven House Capital plc

("Craven House" or the "Company")

Investee company update: RoseMonkey Ltd

The Company confirms that RoseMonkey Ltd (a company in which Craven has a 24.4% shareholding in) has notified it that it has sold certain IP rights and participated in a financing transaction with Quiapeg Pharma AB ("QuiaPeg").

Following completion of the transactions, RoseMonkey was awarded 1,416,007,811 shares in QuiaPeg. RoseMonkey elected to distribute a proportionate amount of those shares to Craven House.

Craven House has therefore received 345,505,096 shares representing 23.2% of QuiaPeg and a market value of approximately $758,792 as at September 9^th, 2024.

QuiaPeg is a drug development company based on a patented drug delivery platform, Uni-Qleaver®, and the company develops improved and patentable forms of drugs under development or already approved by regulatory authorities. QuiaPEG's shares are admitted to trading on Nasdaq First North Growth Market.

Craven House remains a 24.4% shareholder in RoseMonkey Ltd.

For further information please contact:

Craven House Capital Plc Mark Pajak www.Cravenhousecapital.com	Tel: [phone]
SI Capital Broker Nick Emerson www.sicapital.co.uk	Tel: [phone]
SPARK Advisory Partners Limited Nominated Adviser Matt Davis www.Sparkadvisorypartners.com	Tel: [phone]

 About Craven House Capital:

The Company's Investing Policy is primarily to invest in or acquire a portfolio of companies, partnerships, joint ventures, businesses or other assets participating in the e-Commerce sector.

 

END